Hana ʻo AASraw i nā pauka NMN a me NRC i ka nui!

Ibrutinib

  1. Nā lāʻau lapaʻau pahuhopu Ibrutinib (CAS: 936563-96-1)
  2. ʻO Hebutinib Mekanism o ka Hana
  3. Ka mea i hoʻohana ʻia ai ʻo Ibrutinib
  4. Nā kōkua / hopena ʻo Ibrutinib
  5. Pehea mākou e lawe ai iā Ibrutinib
  6. Nā ʻaoʻao ʻaoʻao ʻo Ibrutinib
  7. Ka mālama ʻana ʻo Ibrutinib

Nā Lāʻau Kūpono Ibrutinib(CAS: 936563-96-1)

Nui nā lāʻau lapaʻau hou no ka lymphoma i lāʻau hoʻomāka ʻia. Nā lāʻau i māka ʻia ʻimi e pepehi i ke ʻano o ke keʻa i huli i nā maʻi ʻaʻai a i ʻole hoʻokū i nā hōʻailona e ulu a hoʻokaʻawale paha i nā pūnaʻi maʻi. I ka lymphoma, ua kapa ʻia ke ʻano o ke keʻa e lilo i maʻi ʻaʻaʻi he "lymphocyte" (kahi ʻano o ke keʻokeʻo koko keʻokeʻo e hakakā ana i ka maʻi maʻi). Nui a hewahewa nā ʻano lymphocyte i hiki ke lilo i maʻi ʻaʻai. Pahuhopu ʻo Ibrutinib i nā lymphocytes B (B cells) a no laila hoʻohana ʻia e mālama i nā lymphomas B-cell.

Hoʻouna a loaʻa nā hōʻailona i nā hunaola ʻē aʻe. Mālama kekahi o kēia mau hōʻailona i ke ola o nā hunaola. Nui nā ala hōʻailona a hoʻouna ʻia nā hōʻailona ma hoʻokahi a ʻoi paha o kēia mau ala. ʻO Ibrutinib kahi mea hōʻailona pūkaʻina cell e kuhikuhi i kahi protein i kapa ʻia ʻo 'Bruton' tyrosine kinase '(BTK). ʻO BTK kahi ʻāpana o ke ala e kōkua ai i nā hunaola B e noho ola a mahele. Hiki i ka pale ʻana iā BTK ke make i nā hunaola B a pale iā lākou i ka hoʻokaʻawale ʻana. No laila hiki i kēia lapaʻau ke hoʻopau i ka hoʻolaha ʻana o nā hunaola B maʻi ʻino.

 

Ibrutinib Ka hana hana

Ibrutinib (936563-96-1) ʻaʻole ia he lāʻau chemotherapy akā ʻo kekahi o nā mea i kapa ʻia he "therapies target." ʻO ka hopena pahuhopu ka hopena o nā makahiki o ka noiʻi i hoʻolaʻa ʻia i ka hoʻomaopopo ʻana i nā ʻokoʻa ma waena o nā hunaola maʻi ʻaʻai a me nā hunaola maʻamau. I kēia lā, ua kau nui ka mālama ʻana i ka maʻi ʻaʻai i ka luku ʻana i ka hoʻokaʻawale ʻana i nā hunaola no ka mea ʻo kahi hiʻohiʻona o nā hunaola maʻi ʻo ia ka māhele wikiwiki ʻana. Minamina, ua hoʻokaʻawale wikiwiki ʻia kekahi o kā mākou mau pūnaewele maʻamau, e hoʻoulu ana i nā hopena ʻaoʻao he nui.

Hoʻomakaʻia ka hopena e pili ana i kaʻikeʻana i nā hiʻohiʻona'ē aʻe o nā pūnaepe pūpū. ʻImi nā kānakaʻepekema i nāʻano likeʻole o nā pūnaeho pūpū me nā pūnaewele maʻamau. Hoʻohanaʻia kēiaʻikepili no ka hanaʻana i kahi lāʻau hoʻohālikelike e hōʻeuʻeu i nā pūnaewele kanalē me kaʻole e loaʻa nā pūnaewele maʻamau, a laila e alakaʻi ana i nā hopena piliʻole. ʻO nāʻano o keʻano o keʻano o keʻano heʻe keʻano, heʻano liʻiliʻi wale nō ia, akā, hoʻopili nā mea a pau i ka hikiʻana o ke kiko pukupuku e ulu, puʻunaue, hoʻoponopono a / aiʻole e launa pū me nā pūnaewele'ē aʻe.

Ua pāpā ʻo Ibrutinib i ka hana o ko Bruton's tyrosine kinase (BTK). ʻO ka BTK kahi mole mole hōʻailona o ka B-cell receptor signaling complex e hana nui i ke ola ʻana o nā cell B malignant. Paʻa ʻo Ibrutinib i nā hōʻailona e hoʻonāukiuki i nā pūnaewele B malignant e ulu a māhele i ka kaohi ʻole. Ke hoʻomau nei ka noiʻi e ʻike i nā ʻōpala e mālama maikaʻi ʻia me nā therapies i hoʻomākaukau ʻia a e ʻike i nā pahuhopu hou aʻe no nā ʻano maʻi ʻaʻai.

Hoʻomaopopo: Paipai ikaika mākou iā ʻoe e kamaʻilio me kāu ʻoihana olakino e pili ana i kāu kūlana olakino kikoʻī. ʻO ka ʻikepili i loko o kēia pūnaewele he mea kōkua a hoʻonaʻauao hoʻi, akā ʻaʻole ia he mea pani no ka ʻōlelo aʻoaʻo olakino.

ʻO AASraw ka mea hana ʻoihana ʻo Ibrutinib.

E ʻoluʻolu e kaomi ma aneʻi no ka ʻike ʻōlelo. Hana iā mākou

 

Ka mea i hoʻohana ʻia ai ʻo Ibrutinib

❶ E mālama i ka poʻe me ka limle cell lymphoma (MCL; kahi maʻi ʻaʻai e ulu wikiwiki ana e hoʻomaka i nā hunaola o ka ʻōnaehana pale) i mālama mua ʻia me hoʻokahi lāʻau chemotherapy ʻē aʻe.

❷ E mālama i nā poʻe me leukemia lymphocytic paleka (CLL; kahi ʻano maʻi ʻaʻai e hoʻomaka i loko o nā hunaola keokeo) a me ka lymphocytic lymphoma liʻiliʻi (SLL; kahi ʻano maʻi ʻaʻai e hoʻomaka ka hapanui ma nā lymph node).

Treat E mālama i ka poʻe me ka macroglobulinemia o Waldenstrom (WM; kahi maʻi ʻaʻa e ulu lohi ana e hoʻomaka i kekahi mau kikoʻī koko keʻokeʻo i loko o kou iwi iwi).

Treat E mālama i ka poʻe me ka limfoma palena palena liʻiliʻi (MZL; kahi lohi e ulu nei i ka maʻi ʻaʻai e hoʻomaka i kahi ʻano o nā hunaola keokeo e hakakā maʻamau i nā maʻi) i mālama ʻia me kekahi ʻano chemotherapy chemotherapy.

Treat E mālama i ka poʻe me ka maʻi mau vs. ka maʻi host (cGVHD; kahi pilikia o ka hematopoietic stem-cell transplant [HSCT ) ma hope o ka mālama pono ʻole ʻia me 1 a ʻoi aku paha nā lāʻau.

Aia ʻo Ibrutinib i kahi papa o nā lāʻau i kapa ʻia nā kinase inhibitors. Hana ia ma ke kāpae ʻana i ka hana o ka protein pono ʻole e hōʻailona ai i nā hunaola maʻi ʻaʻai e hoʻonui. Mālama kēia i ka laha ʻana o nā hunaola maʻi ʻaʻai.

Ibrutinib

Ibrutinib maika/ Nā hopena

Ua manaʻo ʻia ʻo Ibrutinib e nā poʻe loea he "breakthrough treatment" no kekahi ʻano o ka lymphoma. Hāʻawi ia i nā helu pane kiʻekiʻe i hoʻohālikelike ʻia me nā therapies ʻē aʻe no nā ʻano like o ka lymphoma. ʻO nā hoʻokolohua nui i alakaʻi ʻia i ka ʻae ʻia o ibrutinib e wehewehe iki ʻia ma lalo.

 

(1) Nā pono i ka limle cell lymphoma

Mantle cell lymphoma i hoʻi hou ʻole a i ʻole i pane ʻole i ka laina laina mua hiki ke paʻakikī ke mālama. Eia nō naʻe, ua hōʻike ʻia ka noiʻi nui ma kēia wahi i ʻoi aku ma mua o ʻelua hapakolu o ka 111 poʻe i mālama ʻia me ibrutinib i pane i ka lapaʻau (ua emi a nalowale paha kā lākou lymphoma).

Hoʻohālikelike kahi noiʻi ʻelua ma 280 poʻe i ka ibrutinib me kahi lāʻau ʻino ʻē aʻe, temsirolimus, i ka poʻe me ka lympoma pūlepele a me ka refactory lymphoma. Ua noho ka poʻe no ka awelika o 15 mau mahina me ka ʻole e hele a hewa ʻole ko lākou lymphoma ke mālama ʻia me ibrutinib i hoʻohālikelike ʻia me ka awelika o 6 mau mahina ke mālama ʻia me temsirolimus.

 

(2) Nā kōkua i ka leukemia lymphocytic mau (CLL)

Ua ʻike ʻia nā pane lōʻihi i nā poʻe me CLL i mālama ʻia me ibrutinib. I ka hoʻokolokolo nui e pili ana i nā poʻe 391 me CLL relacted a i ʻole refactory, ua hoʻohālikelike ʻia ʻo ibrutinib me ofatumumab, i hoʻohana pinepine ʻia no ka poʻe me CLL i hoʻi mai. Hoʻokahi makahiki ma hope o ka hoʻomaka ʻana o ka lapaʻau ʻana, ma kahi o 66 a 100 mau poʻe e lawe ana i ka ibrutinib i loaʻa ka CLL i noho kaohi ʻia (ua kapa ʻia kēia ʻo 'ke ola ʻole me ka holomua') hoʻohālikelike ʻia me 6 ma 100 mau kānaka i mālama ʻia me ka ofatumumab.

I loko o kahi noi ʻelua e pili ana i ka 269 poʻe i loaʻa ʻole ka lāʻau no kā lākou CLL, ua hoʻohālikelike ʻia ʻo ibrutinib me ka lāʻau chemotherapy chlorambucil. Ma hope o 1.5 mau makahiki o ka mālama ʻana, ma kahi o 90 a 100 mau poʻe e lawe ana i ka ibrutinib i loaʻa ka CLL i noho kaohi ʻia ma ka hoʻohālikelike ʻia me kahi o 52 a 100 mau poʻe i mālama ʻia me chlorambucil.

Hoʻohui pū ʻia ʻo ibrutinib i bendamustine a me rituximab no ka poʻe me CLL relacted a refactory paha i maikaʻi i kahi noiʻi e pili ana i 578 poʻe. Ua hoʻemi ʻia ka makaʻu o ka holomua o CLL ma o ka lawe ʻana i ibrutinib ma kahi o kahi placebo (dummy treatment).

 

(3) Nā kōkua i Waldenström' s macroglobulinaemia (WM)

Ua ʻike ʻia kahi helu pane kiʻekiʻe i nā poʻe me WM - ma kahi o 9 i 10 mau poʻe me WM i pane i lāʻau lapaʻau ibrutinib i kahi hoʻokolokolo ma 63 poʻe. He hopena nui kēia hoʻokolohua no WM no ka mea he ʻano maʻamau ʻole ia o ka lymphoma a no laila paʻakikī e kiʻi i ka nui o ka poʻe e komo i kahi hoʻokolohua hoʻokolohua. ʻO kēia hoʻokolokolo i alakaʻi ʻia i ka ʻae o ibrutinib no WM ma ʻEulopa.

 

Pehea mākou e lawe ai Ibrutinib 

E hāʻawi ʻia ʻoe iā ibrutinib ma ke ʻano he papa. Hāʻawi ʻia ia i ka hui pū ʻia me nā lāʻau hoʻomohala hoʻomōhala ʻē aʻe a me chemotherapy. I ka wā o ka hoʻomaʻamaʻa ʻike pinepine ʻoe i kahi kauka lapaʻau cance¬r, kahi kahu maʻi maʻi ʻaʻai a i ʻole kahu hānai kūikawā, a me kahi kauka lāʻau lapaʻau loea. ʻO ia ka mea a mākou e ʻōlelo ai ke haʻi mākou i ke kauka, kahu a mea hoʻomalu paha i kēia ʻike.

Ma mua a ma ka lā o ka mālama ʻana, e lawe kahi kahu hānai a kanaka paha i hoʻomaʻamaʻa e lawe i ke koko (phlebotomist) i kahi laʻana koko mai ou aku. E nānā kēia inā aia kou mau huna koko i kahi pae palekana nāu e mālama ai.

E ʻike ʻoe i ke kauka a kahu wahine paha ma mua o kou mālama ʻana. E nīnau lākou iā ʻoe pehea kou ʻano. Inā maikaʻi nā hopena o kou koko, e hoʻomākaukau ka kauka lāʻau i kāu lāʻau. E haʻi aku kāu kahu iā ʻoe i ka mākaukau o kāu lāʻau.

Hāʻawi ke kahu a mea kauka iā ʻoe i nā papa ibrutinib e hoʻi i kou home. Lawe mau iā lākou e like me ka wehewehe ʻana. He mea nui kēia e ʻike pono e holo pono ana nā mea āpau iā ʻoe. Hāʻawi ʻia ʻoe i nā papa o nā ikaika ʻokoʻa. Mālama mau ʻoe lawe ana i ka ibrutinib i kēlā me kēia lā no ka mea e mālama ka maʻi ʻaʻai. Hāʻawi paha kāu kahu a mea kauka paha iā ʻoe i nā lāʻau anti-maʻi a me nā lāʻau ʻē aʻe e lawe i ka home. E lawe i kāu mau papa āpau e like me ka wehewehe ʻana iā ʻoe.

ʻO AASraw ka mea hana ʻoihana ʻo Ibrutinib.

E ʻoluʻolu e kaomi ma aneʻi no ka ʻike ʻōlelo. Hana iā mākou

 

Kōma Homo ma mālama pilikino

ʻOiai ke lawe nei iā ibrutinib, inu ʻelua a ʻekolu paha mau kuata o ka wai i kēlā me kēia 24 hola, ke ʻole ʻoe e kuhikuhi ʻē ʻia.

♦ E holoi pinepine i kou mau lima a ma hope o ka lawe ʻana i kēlā me kēia kaha o ka ibrutinib.

♦ makaʻu paha ʻoe i ka maʻi maʻi a no laila e hoʻāʻo e hōʻalo i ka lehulehu a i ʻole ka poʻe me ke anu, a hōʻike i ke kuni a i ʻole nā ​​hōʻailona ʻino ʻē aʻe i kāu kauka olakino.

♦ E kōkua i ka mālama ʻana / pale ʻana i nā ʻeha o ka waha ke lawe nei ʻoe i ka ibrutinib, e hoʻohana i kahi palaki niho palupalu, a holoi i ʻekolu mau manawa i ka lā me 1 teaspoon o ka soda bakena i hui ʻia me 8 auneke wai.

♦ E hoʻohana i kahi pahi uila a me kahi palaki niho palupalu e hōʻemi i ke kahe ʻana o ke kahe.

♦ E hōʻalo i nā haʻuki a i ʻole nā ​​hana e hōʻeha ai.

♦ I mea e hōʻemi ai i ka nausea, e lawe i nā lāʻau anti-nausea e like me ka mea i kauoha ʻia e kāu kauka, a ʻai i nā mea liʻiliʻi a pinepine i ka lawe ʻana i ka ibrutinib

♦ ʻAi i nā meaʻai i hiki ke kōkua i ka hōʻemi ʻana i ka maʻi palahalaha - see Managing Side Effects - Diarrhea

♦ E hāhai i ka lāʻau o anti-diarrhea lapaʻau e like me ka mea i kauoha ʻia e kāu ʻoihana mālama ola.

♦ Hōʻalo i ka puka ʻana o ka lā. E ʻaahu i ka SPF 15 (a ʻoi paha ke kiʻekiʻe) ka pale o ka lā a me nā lole pale. E hoʻomaʻamaʻa paha ʻo Ibrutinib iā ʻoe i ka lā a maʻalahi hoʻi ʻoe i ka lā.

♦ Ma ka laulā, pono e mālama i ka inu ʻana i nā mea inu ʻona me ka liʻiliʻi a hōʻalo loa ʻia i ka wā e lawe ana ʻoe i ka ibrutinib. Pono ʻoe e kūkākūkā i kēia me kāu kauka.

♦ E hoʻomaha nui.

♦ Mālama i ka meaʻai maikaʻi i ka wā e mālama ʻia me ibrutinib.

♦ Inā ʻike ʻoe i nā ʻōuli a i ʻole nā ​​hopena i ka wā e mālama ʻia me ibrutinib, e noʻonoʻo pono e kūkākūkā me lākou me kāu hui mālama ola. Hiki iā lākou ke kuhikuhi i nā lāʻau a / a hāʻawi i nā manaʻo ʻē aʻe i kūpono i ka mālama ʻana i ia mau pilikia.

 

Ibrutinib Side Ehelehelena

E kiʻi i ke kōkua lapaʻau kūikawā inā loaʻa iāʻoe nā hōʻailona o ka hopena maʻi: hives; ka hanu pilikia; ka pehu o kou mau maka, kou lehelehe, kou lehelehe, a me kou puʻu.

 

Kāohi i ka hoʻohana ʻana iā ibrutinib a kāhea koke aku i kāu kauka inā loaʻa iā ʻoe:

♦ Nā hōʻailona o ka maʻi ʻaʻai – ke kuni, ka haʻalulu, nāwaliwali, nā ʻeha o ka waha, ka maʻi me ka ʻūhū, ka hanu pilikia;

♦ Nā hōʻailona o ke kahe ʻana i loko o kou kino – ka paupauaho, nāwaliwali, huikau, nā pilikia me ka ʻōlelo, hoʻolōʻihi ʻia ke poʻo, nā ʻeleʻele a i ʻole ke koko, a i ʻole ka mumū i ke koko a i ʻole ka luaʻi e like me nā kumu kope;

♦ ʻO ka maʻi ahulau nui a hoʻomau paha;

ʻO ka ʻeha o ka umauma, ke kuʻi ʻana o ka puʻuwai a i ʻole ke kīkē ʻana i kou umauma, ke manaʻo nei ʻoe e hele i waho;

♦ ʻeha ke poʻo, ʻike maka ʻole, kuʻi i kou ʻāʻī a pepeiao paha;

♦ ʻĀpiki maʻalahi, hoʻokahe koko ʻole, poni a ʻulaʻula hoʻi ma lalo o kou ʻili;

♦ ʻili pale, nā lima a me nā wāwae anuanu;

♦ Nā pilikia o ka hakuʻala – liʻiliʻi a i ʻole ka mimiki ʻana, ka pehu ʻana i kou mau wāwae a i ʻole nā ​​kuʻekuʻe wāwae. a i ʻole

♦ Hōʻailona o ka haki o ka puʻupuʻu tuma – huikau, nāwaliwali, nākiʻi o nā mākala, nausea, ka luaʻi, ka wikiwiki a mālie paha o ka puʻuwai, hoʻemi i ka urination, ʻūlū i kou mau lima a me kou mau wāwae a i ʻole kou waha.

 

Hiki ke komo i nā hopenaʻaoʻao maʻamau:

♦ Diarrhea, nausea;

♦ Fever, batukū, pilikia hanu;

♦ Pālū a i ʻole ulcer i kou waha;

♦ Luhi luhi;

♦ Bruising, ʻāwīwī; a i ʻole

♦ ʻeha ʻeha, ʻehaʻeha ka iwi.

ʻAʻole kēia he papa inoa piha o nā hopena pili a hiki i nā mea'ē aʻe. Kāhea i kāu kauka no ka'ōlelo aʻo kino no nā hopenaʻaoʻao. Hiki iāʻoe ke hōʻike i nā hopena'ē aʻe i ka FDA ma 1-800-FDA-1088.

ʻO AASraw ka mea hana ʻoihana ʻo Ibrutinib.

E ʻoluʻolu e kaomi ma aneʻi no ka ʻike ʻōlelo. Hana iā mākou

 

Ibrutinib Ska hoʻokele

E mālama iā Ibrutinib i loko o ka pahu i komo ai, pani paʻa ʻia, a ʻaʻole hiki i nā keiki. E mālama iā ia i ka mahana wela o ka lumi a mamao aku mai ka mālamalama, ka wela a me ka ona mau ʻole i loko o ka lua.

Pono e hoʻolei ʻia ʻo Ibrutinib i makemake ʻole ʻia i nā ala kūikawā e hōʻoia ʻole i ka make ʻana o nā holoholona, ​​nā keiki, a me nā poʻe ʻē aʻe iā lākou. Eia naʻe, ʻaʻole pono ʻoe e kaomi i kēia Ibrutinib i lalo i ka lua. Akā, ʻo ke ala ʻoi loa e hoʻolilo i kāu lāʻau i loko o kahi papahana hoʻihoʻi lāʻau. E kamaʻilio me kāu kauka lāʻau a kāhea paha i kāu ʻōpala a me nā hana hoʻopōʻaiapuni kūloko e aʻo e pili ana i nā papahana hoʻihoʻi i kou kaiāulu. E ʻike i ka hoʻolei palekana ʻana o ka FDA

He mea nui ka mālamaʻana i nā lāʻau a pau mai kaʻikeʻana a hiki i nā keiki e like me nā pahu (e like me nā pilina o ka pule hebedoma a me ka mea no nā maka o ka maka, ka'ōpū, nā pāpale, a me nā mea inu)ʻaʻole hiki ke kū'ē i ka'ōpiopio a hiki i nā keiki'ōpiopio ke wehe iā lākou. No ka paleʻana i nā keiki liʻiliʻi mai ka lāʻauʻawaʻawa, e hoʻopaʻa mau i nā piko palekana a kau koke i ka lāʻau i kahi wahi palekana - kahi eʻoi aku ana i waho a ma waho aku o ko lākou mau maka a hiki.

 

Reference

[1] Brown JR, Hillmen P, O'Brien S, et al. Hoʻonui ʻia ka ukali ʻana a me ka hopena o nā mea wānana weliweli kiʻekiʻe mai ka pae 3 RESONATE hoʻopaʻa haʻawina i nā mea maʻi me CLL / SLL i mālama mua ʻia [paʻi ʻia ma ka pūnaewele ma mua o ka paʻi 8 Iune 2017]. Leukemia.

[2] Byrd JC, Brown JR, O'Brien S, et al; NĀ NĀ NĀ NĀ HUʻI NUI ʻO Ibrutinib me ka ofatumumab i mālama mua ʻia i ka leukemia lymphoid mau. N Engl J Med. 2014; 371 (3): 213-223.

[3] Byrd JC, Furman RR, Coutre SE, et al. ʻEkolu makahiki ka ukali ʻana o ka lapaʻau-naif a me nā mea maʻi i hana mua ʻia me CLL a me SLL e loaʻa ana iā ibrutinib kahi agena hoʻokahi. Koko. 2015; 125 (16): 2497-2506.

[4] Mato AR, Hill BT, Lamanna N, et al. ʻO ke kaʻina optimum o ibrutinib, idelalisib, a me venetoclax i ka leukemia lymphocytic mau: ʻo nā hopena mai kahi noiʻi multicenter o 683 mau maʻi. ʻO Ann Oncol. 2017; 28 (5): 1050-1056.

[5] ʻO Woyach JA, Ruppert AS, Guinn D, et al. ʻO BTKC481S-kūpaʻa kūpaʻa i ibrutinib i ka leukemia lymphocytic mau. ʻO J Clin Oncol. 2017; 35 (13): 1437-1443.

[6] Winqvist M, Asklid A, Andersson PO, et al. Nā hualoaʻa maoli o ka ibrutinib i nā mea maʻi me ka leukemia lymphocytic mau maʻi relapsed a refactory paha: nā ʻike mai 95 mau kānaka maʻi i mālama ʻia i loko o kahi papahana hoʻohana aloha. ʻO kahi hoʻopaʻa noiʻi mai ka hui ʻo Chronicle Lymphocytic Leukemia. Haematologica. 2016; 101 (12): 1573-1580.

[7] Jones JA, Hillmen P, Coutre S, et al. Hoʻohana o nā anticoagulants a me antiplatelet i nā mea maʻi me ka leukemia lymphocytic mau e mālama ʻia me hoʻokahi agrr ibibutinib. Br J Haematol. 2017; 178 (2): 286-291.

[8] Kamel S, Horton L, Ysebaert L, et al. Ua pāpā ʻo Ibrutinib i ka collagen-mediated akā ʻaʻole ka ADP-mediated platelet aggregation. Leukemia. 2015; 29 (4) 783-787.

[9] Rigg RA, Aslan JE, Healy LD, et al. ʻO ka lawelawe waha o kā Bruton's tyrosine kinase inhibitors e hoʻopilikia i ka hana platelet i hoʻopili ʻia e GPVI. ʻO Am J Physiol Pūnaewele Physiol. 2016; 310 (5): C373-C380.

[10] Wang ML, Rula S, Martin P, et al. ʻO ka māka ʻana iā BTK me ibrutinib i ka lymphoma mantle-cell relapsed a i ʻole refactory. N Engl J Med. 2013; 369 (6): 507-516.

[11] Treon SP, Tripsas CK, Meid K, et al. ʻO Ibrutinib i mālama ʻia ma ma mua o Waldenström's macroglobulinemia. N Engl J Med. 2015; 372 (15): 1430-1440.

[12] Lampson BL, Yu L, Glynn RJ, et al. ʻO nā arrhythmia Ventricular a me ka make koke i nā maʻi e lawe ana iā ibrutinib. Koko. 2017; 129 (18): 2581-2584.

[13] ʻO Tedeschi A, Frustaci AM, Mazzucchelli M, Cairoli R, Montillo M. Pono ʻia ka HBV prophylaxis i ka wā o CLL me ibrutinib? Leuk Lymphoma. 2017; 58 (12): 2966-2968.

[14] ʻO Sun C, Tian X, Lee YS, et al. Hoʻohui hou ʻia ka palekana o ka humoral a me nā maʻi liʻiliʻi i nā mea maʻi me ka leukemia lymphocytic mau e mālama ʻia me ibrutinib. Koko. 2015; 126 (19): 2213-2219.

[15] Ruchlemer R, Ben Ami R, Lachish T. Ibrutinib no ka leukemia lymphocytic mau. N Engl J Med. 2016; 374 (16): 1593-1594.

[16] Ahn IE, Jerussi T, Farooqui M, Tian X, Wiestner A, Gea-Banacloche J. Atypical Pneumocystis jirovecii pneumonia i nā mea maʻi i mālama ʻole ʻia me CLL ma hoʻokahi agrr ibibutinib. Koko. 2016; 128 (15): 1940-1943.

[17] Vitale C, Ahn IE, Sivina M, et al. ʻO nā cytopenias autoimmune i nā mea maʻi me ka leukemia lymphocytic mau e mālama ʻia me ibrutinib. Haematologica. 2016; 101 (6): e254-e258.

[18] Lip GY, Pan X, Kamble S, et al. ʻO ka pilikia nui o ke kahe ma waena o nā mea maʻi atrial non-valvular atrial fibrillation i hoʻomaka ʻia ma apixaban, dabigatran, rivaroxaban a i ʻole warfarin: kahi noiʻi nānā "honua maoli" ma United States. Hoʻomaʻamaʻa Int J Clin. 2016; 70 (9): 752-763.

0 Likes
118 Views

E hiki no hoi i like

Comments ua paa.